Support in USA : 1-978- 707-9553 / Support in India : +91- 9987711567

  • Apple Pharmaceuticals

Glivec 400 mg

Anticancer-Cancer-Treatment-Novartis-Imatinib-Mesylate-400mg-Glivec

Availability: In stock

Special Price $ 325

BRAND : Glivec 400 mg
STRENGTH : 400mg
INGREDIENT : Anticancer-Cancer-Treatment-Novartis-Imatinib-Mesylate-400mg-Glivec
COMPANY NAME : Novartis
COUNT : 30 Tablets



Description of Glivec 400 mg

Brand name: Glivec
Generic name: Imatinib mesylate
Manufacturer: Novartis
Strength: 400mg
Category: Anti-neoplastic agent
Container: 30 tablets in a bottle
Product Description:
Glivec tablet is an anti cancer medicine which is useful for treating;
• Advanced myelogenous leukemia (CML),
• Gastrointestinal stromal tumors (GISTs) and a number of malignancies
Glivec is a tyrosine kinase inhibitor that prohibits BCR-ABL kinase produced by chromosomal rearrangement in chronic myeloid leukemia and acute lymphoblastic leukemia
PDG-derived tyrosine kinase that are expressed in gastrointestinal stromal tumor
Glivec is used as monotherapy, or it may combine with some other medicine in the conditions of certain types of cancer or bone marrow disorders.

Pharmacology of Glivec 400 mg

Mechanism of action:
Glivec contains an active chemical substance known as Imatinib mesylate; it is an inhibitor of certain tyrosine kinase enzymes.
Glivec prohibits BCR-ABL tyrosine kinase (atypical enzyme produced by Philadelphia chromosome abnormality in CML)
Glivec obstruct the multiplication and promote the apoptosis in BCR-ABL positive cells in addition to fresh leukemia cells from Philadelphia chromosome positive CML
Glivec also prohibits tumor growth of BCR-ABL transacted murine myeloid cells along other BCR-ABL positive leukemia CML in blast crisis
Glivec inhibits receptor tyrosine kinase for platelet-derived growth factor (PDGF), stem cell factor (SCF) and PDGF and SCF mediated cellular events get prohibited.
Pharmacodynamic:
 Imatinib a 2-phenylaminopyrimidine, it acts as a tyrosine kinase enzyme inhibitor.
 In malignancy conditions, Philadelphia chromosome leads to fusing of protein with BCR (breakpoint cluster region). Glivec used to reduced Bcr-Abl activity
Pharmacokinetic:
Absorption:
After an oral administration of Glivec tablets, it is largely absorbed within 2-4 hours. The bioavailability of Glivec tablets is about 98%.
Distribution:
Imatinib is highly bound to the human plasma protein almost range of 95%. It is mostly bound to albumin and α1-acid glycoprotein.
Metabolism:
The major enzyme which is essential for metabolism of Glivec tablet is CYP3A4.
Active metabolite of Imatinib is N-demethylated piperizine derivative
Excretion:
The elimination of Imatinib is predominantly occurred in feces.
Nearly 81% of the drug excreted within 7 days through feces and 13% of drug through urine.
The half life time of Imatinib and active metabolite N-demethyl derivative (CGP74588) are around 18 and 40 hours respectively.

Indication of Glivec 400 mg

Glivec tablets are primarily indicated for the treatment of;
Aggressive systemic mastocytosis
Chronic esinophillic leukemia
Dermatofibrosarcoma protuberans
Gastrointestinal stromal tumors
Hyperesinophillic syndrome
Myelodysplastic syndrome
Myeloproliferative disease
Philadelphia chromosome positive acute lymphoblastic leukemia
Philadelphia chromosome positive chronic myeloid leukemia

Dose & Dosage's of Glivec 400 mg

The prescribed dose of tablet Glivec is 400mg or 600mg as a single dose. Whereas 800mg which is administered as 400mg twice daily.
Glivec tablets should be taken with food
The recommended dose for following conditions;
Acute lymphoblastic leukemia:
In adults, the recommended dose is 600mg should be taken orally as a single dose.
Myelodysplastic/Myeloproliferative diseases:
The prescribed dose is 400mg PO qDay
Hyperesinophillic syndrome:
In this condition, prescribed dose is 400mg PO qDay
Chronic myeloid leukemia:
Chronic phase: In newly diagnosed patients, the dose of Glivec tablet is 400mg should be orally taken as a single dose.
If chronic phase is failed with the treatment of interferon alpha therapy; dose is increased to 600mg per day.
Accelerated phase: 600mg PO qDay; dose should be vary to 400mg PO as twice daily if there is no severe adverse drug reaction or non leukemia associated neutropenia or thrombocytopenia.
Dermatofibrosarcoma protuberans:
Recommended dose is 400mg PO q12hr
Mastocytosis:
Without D816V c-kit mutation: 100mg per oral for qDay
c-kit mutational status unknown: 400mg per oral qDay
ASM related with esinophillic: 100mg PO qDay initially increased to 400mg/day.
Gastrointestinal stromal tumors
The prescribed dose of the tablet Glivec is 400mg should be taken orally as a twice daily
In pediatric:
Chronic myeloid leukemia:
<1 year: the safety and efficacy of the drug has not been established
≥1 year: 340mg/m2/day PO; should not be exceed 600mg/day
Acute lymphoblastic leukemia:
<1 year: the safety and efficacy of the drug has not been established
≥1 year: 340mg/m2/day PO; should not be exceed 600mg/day.
Missed dose:
If patient fail to take Glivec tablet, patient should administered within a time.
Otherwise, tablet should be discontinued and follow the next drug schedule.

Side Effects of Glivec 400 mg

Cardiac disorders:
Palpitations, pericardial effusion, congestive cardiac failure, tachycardia, pulmonary edema, arrhythmia, atrial fibrillation, cardiac arrest, myocardial infarction, angina pectoris
Vascular disorders:
Flushing, hemorrhage, hypertension, peripheral coldness, Reynaud’s phenomenon, elevated LDH levels
Skin disorders:
Dry skin, alopecia, face edema, Erythema, photosensitivity reactions, nail disorder, purpura, psoriasis, rashes, vascular rash, Stevens Johnson syndrome, acute febrile neutrophillic dermatosis.
Gastrointestinal disorders:
Abdominal distension, gastro esophageal reflux, dry mouth, gastritis, gastric ulcer, stomatitis, mouth ulcer, eructation, esophagitis, dysphasia, and pancreatitis
General disorders:
Weakness, anasarca, chills, malaise
Blood and lymphatic system:
Pancytopenia, febrile neutropenia, Lymphopenia, esinophillia, thrombocythemia, bone marrow depression, lymphadenopathy, hemolytic anemia, Aplastic anemia
Hepatobiliary:
Hepatitis, jaundice, hepatic failure, hepatic necrosis
Immune system:
Angioedema
Metabolism and nutrition:
Weight decreased, loss of appetite, dehydration, gout, hyperuricemia, hypocalcaemia, hyperglycemia, hyponatremia, hyperkelamia, hypomagnesemia
Musculoskeletal:
Joint swelling, muscle stiffness, muscular weakness, arthritis
Nerve system:
Paresthesia, hypesthesia, syncope, peripheral neuropathy, somnolence, tremor
Renal and urinary disorders:
Urine frequency increased, Hematuria, renal pain, renal failure
Reproductive system:
Nipple pain, scrotal edema, Breast enlargement, menorrhagia, sexual dysfunction, gynecomastia, erectile dysfunction, menstruation irregular,
Pulmonary, thoracic:
Epistaxis, pleural effusion, interstitial pneumonitis, pulmonary fibrosis, pulmonary hypertension, pulmonary hemorrhage
Eye, ear and labyrinth disorders:
Eye irritation, eye pain, scleral hemorrhage, retinal hemorrhage, papilla edema, glaucoma, Conjunctivitis, vision blurred, orbital edema, conjuctival hemorrhage, dry eye, vertigo, tinnitus,

Contraindication of Glivec 400 mg

Hypersensitive reaction to Imatinib mesylate and other excipients present in Glivec tablets.

Drug Interaction of Glivec 400 mg

Glivec tablets are primarily indicated for the treatment of; Aggressive systemic mastocytosis Chronic esinophillic leukemia Dermatofibrosarcoma protuberans Gastrointestinal stromal tumors Hyperesinophillic syndrome Myelodysplastic syndrome Myeloproliferative disease Philadelphia chromosome positive acute lymphoblastic leukemia Philadelphia chromosome positive chronic myeloid leukemia

Precaution of Glivec 400 mg

Caution with use in hepatic impairment patients
Avoid combination with strong CYP3A4 inducers
Risk of severe CHF or ventricular dysfunction
Hemorrhage occurs
Growth retardation occurs in children

Usage & Safety profile of Glivec 400 mg Pregnancy & Lactation

Pregnancy category: D Glivec should not recommended to pregnant and breast feeding mothers, it can able to cause fetal malformations and cause fetal harm The metabolites excreted in human milk

Storage of Glivec 400 mg

Glivec tablet container should be stored in cool and dry place
It should be keep away from moisture, heat and light